Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Achimastos A, Alexandrides T, Alexopoulos D, Athyros V, Bargiota A, Bilianou E, Chrysochoou C, Drogari E, Elisaf M, Ganotakis E, Goudevenos I, Ioannidis I, Kolovou G, Kotsis V, Lekakis I, Liberopoulos E, Melidonis A, Nikolaou V, Ntaios G, Papanas N, Pappas S, Pitsavos C, Rallidis L, Richter D, Skoumas I, Tentolouris N, Tousoulis D, Tselepis A, Tsioufis K, Tziakas D, Tziomalos K, Vardas P, Vlachopoulos C, Vlahakos D. Achimastos A, et al. Among authors: bargiota a. Hormones (Athens). 2016 Jan-Mar;15(1):8-14. doi: 10.14310/horm.2002.1659. Hormones (Athens). 2016. PMID: 27086681 Free article.
The ongoing challenge of discrepant growth hormone and insulin-like growth factor I results in the evaluation of treated acromegalic patients: a systematic review and meta-analysis.
Kanakis GA, Chrisoulidou A, Bargiota A, Efstathiadou ZA, Papanastasiou L, Theodoropoulou A, Tigas SK, Vassiliadi DA, Tsagarakis S, Alevizaki M. Kanakis GA, et al. Among authors: bargiota a. Clin Endocrinol (Oxf). 2016 Nov;85(5):681-688. doi: 10.1111/cen.13129. Epub 2016 Jul 14. Clin Endocrinol (Oxf). 2016. PMID: 27292418 Review.
Real-World Adequacy of Glycaemic Control in Treatment-Naïve Greek Patients with Type 2 Diabetes Mellitus Initiating Treatment with Metformin Monotherapy at the Maximum Tolerated Dose: The Reload Study.
Tsimihodimos V, Bargiota A, Pagkalos EM, Manes C, Papas A, Karamousouli E, Voss B, Elisaf MS. Tsimihodimos V, et al. Among authors: bargiota a. Exp Clin Endocrinol Diabetes. 2020 Apr;128(4):224-230. doi: 10.1055/a-0824-6607. Epub 2019 Jan 22. Exp Clin Endocrinol Diabetes. 2020. PMID: 30669167
Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
Cannon AJ, Bargiota A, Billings L, Hunt B, Leiter LA, Malkin S, Mocarski M, Ranthe MF, Schiffman A, Doshi A. Cannon AJ, et al. Among authors: bargiota a. J Manag Care Spec Pharm. 2020 Feb;26(2):143-153. doi: 10.18553/jmcp.2019.19035. Epub 2019 Dec 19. J Manag Care Spec Pharm. 2020. PMID: 31856636 Free PMC article. Clinical Trial.

This short-term (1-year) cost-effectiveness analysis was conducted from the perspective of a U.S. health care payer. RESULTS: More patients achieved HbA1c < 7.5% (P < 0.0001) and < 8.0% (P = 0.0003), and a similar percentage achieved HbA1c 9.0% with IDegLir

…
This short-term (1-year) cost-effectiveness analysis was conducted from the perspective of a U.S. health care payer. RESULTS: More pa …
81 results